Cullinan Initiates NDA Submission for Zipalertinib Combo in First-Line EGFR ex20ins NSCLC Under FDA RTOR
CGEM has more than doubled off its 52-week low of $5.68.
Summary
Cullinan initiated an NDA submission for zipalertinib plus chemotherapy in first-line EGFR ex20ins NSCLC under FDA's RTOR program, with completion expected by year-end 2026. The company is eligible for up to $130M in milestone payments from Taiho upon U.S. approvals.
Key Events · Product Development and Regulatory · CGEM
-
NDA Submission Initiated Under RTOR
Cullinan initiated an NDA submission to the FDA for zipalertinib plus platinum-based chemotherapy in first-line EGFR ex20ins NSCLC under the Real-Time Oncology Review program, with completion expected by year-end 2026.
-
Milestone Payments Up to $130M
Cullinan is eligible for a $30M payment from Taiho upon second-line U.S. approval and up to $100M upon first-line U.S. approval of zipalertinib.
-
Phase 3 REZILIENT3 Basis
The NDA is based on the Phase 3 REZILIENT3 trial, which met its primary endpoint with a statistically significant improvement in median progression-free survival for zipalertinib plus chemotherapy versus chemotherapy alone.
-
Second-Line PDUFA Date Set
A separate NDA for zipalertinib monotherapy in second-line EGFR ex20ins NSCLC remains under FDA review with a PDUFA target action date of February 27, 2027.
Analysis · CGEM · Life Sciences
Cullinan has formally initiated the NDA submission for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion NSCLC under the FDA's Real-Time Oncology Review program, with completion expected by year-end 2026. This is a major regulatory step that moves the company's lead oncology asset toward a potential first-line approval, building on the positive Phase 3 REZILIENT3 data disclosed in August and September. The filing also quantifies the financial upside: up to $130 million in milestone payments from Taiho upon U.S. approvals. For a company with a $935 million market cap and $356 million in cash, these milestones are meaningful but not transformative; the real value is the expanded commercial opportunity in the first-line setting, which is substantially larger than the second-line indication already under FDA review.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 36.8% of the 982 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGEM was trading at $14.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $935.1M. The 52-week trading range was $5.68 to $23.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.